<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638118</url>
  </required_header>
  <id_info>
    <org_study_id>M016455A_4146</org_study_id>
    <nct_id>NCT00638118</nct_id>
  </id_info>
  <brief_title>Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen</brief_title>
  <official_title>A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Examine the relative potency, onset of action and duration of action of fexofenadine HCl 180
      mg (Allegra) and montelukast sodium 10 mg (Singulair) as compared to placebo on skin wheals
      and flares induced by seasonal allergen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of change in skin flares from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size of change in skin wheals from baseline will be measured.</measure>
    <time_frame>Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">48</enrollment>
  <condition>Allergic Rhinitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fexofenadine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, 15 to 55 years of age, may participate.

          -  Subjects with a history of seasonal allergic rhinitis (due to ragweed; oak, elm or
             maple; or grasses) for the previous 2 years.

          -  Positive seasonal allergen skin prick tests (or duplicate seasonal allergen skin prick
             test) with a summation flare greater than or equal to 20 mm larger than diluent
             control, and summation wheal greater than or equal to 6 mm larger than diluent control
             at the screening visit 1 (see Appendix 17.1); the seasonal allergen testing that
             results in the greatest summation flare will be used for all subsequent seasonal
             allergen testing.

          -  All female subjects must have a negative urine pregnancy test at the screening visit.

          -  Female subjects who are sexually active will be expected to use one of the following
             birth control methods throughout the study.

          -  Subjects must be within 15% of normal body weight for height or a BMI less than 29.9
             (based on NHLBI guidelines).

          -  Subjects willing and able to adhere to visit schedules and all study requirements.

          -  All female subjects must have a negative urine pregnancy test at each treatment visit
             (Visit 2, 4, and 6).

          -  Continues to meet all inclusion and exclusion criteria.

        Exclusion Criteria:

          -  Asthma that requires treatment with medication other than an inhaled, short-acting
             beta agonist.

          -  Significant signs and symptoms of currently active allergic disease (SAR, perennial
             allergic rhinitis, episodic allergic rhinitis).

          -  Upper respiratory tract infection, sinusitis, asthma or flu-like symptoms within 2
             weeks prior to visit 1.

          -  Subjects who have dermatographism or other skin conditions which might interfere with
             the interpretation of the skin test results.

          -  Subjects who are receiving escalating doses of immunotherapy, oral immunotherapy or
             short course (rush) immunotherapy.

          -  Any excessive amounts of alcohol (no more than two drinks/day on average).

          -  Any excessive use of caffeine (more than six cups of coffee per day or equivalent).

          -  Any history of chronic alcohol or mood-altering drug abuse.

          -  Any use of tobacco/nicotine products within 90 days of visit 1.

          -  Any disease state or surgery known to affect the gastrointestinal absorption of drugs.

          -  Known hypersensitivity to the investigational product or to drugs with similar
             chemical properties.

          -  Subjects who will be visiting a tanning salon during the study.

          -  Subjects who will need to use artificial tanning products during the study.

          -  Pregnancy.

          -  Breast-feeding.

          -  Regular treatment with other H1-receptor antagonists in the last year before study
             entry.

          -  No person or child of a person directly associated with the administration of the
             study may participate as a study subject.

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the clinical study protocol.

          -  Treatment with any investigational product in the last 30 days before study entry.

          -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other major
             systemic disease making implementation of the protocol or interpretation of the study
             results difficult.

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study.

          -  Subject unlikely to comply with protocol, e.g., uncooperative attitude, inability to
             return for follow-up visits, and unlikelihood of completing the study.

          -  Use of any of the following drugs within the time indicated prior to the first dosing
             visit: Systemic or injected corticosteroids (including oral, parenteral, intravenous,
             rectal) 30 days; Nasal or inhaled or ocular corticosteroids 30 days; Nasal or inhaled
             ipratropium bromide (or atropine), inhaled nedocromil, or nasal, inhaled, or
             ophthalmic sodium cromolyn 14 days; Agents with antihistaminic/anticholinergic
             activity (e.g. antidepressants, antipsychotics) 14 days; Leukotriene pathway modifiers
             (Accolate, Singulair, Zyflo) 10 days; Ocular anti-allergy medications including
             lodoxamide (Alomide), olopatadine (Patanol), emedastine difumarate (Emadine),
             levocabastine (Livostin) 10 days; Non-steroidal anti-inflammatory ophthalmics
             including ketorolac (Acular), flurbiprofen (Ocufen), suprofen (Profenal), diclofenac
             (Voltaren) 10 days; Antihistamines including desloratadine (Clarinex), loratadine
             (Claritin) 10 days; Antihistamines including fexofenadine HCl (Allegra), cetirizine
             (Zyrtec), hydroxyzine, azelastine nasal spray (Astelin), clemastine 7 days; Other
             short-acting antihistamines such as chlorpheniramine or drugs with antihistaminic
             activity 3 days; OTC oral antihistamines, decongestants (includes pseudoephedrine and
             other decongestants), or antihistamines/decongestant combinations including all cold,
             cough, and sleep aids 3 days; OTC ophthalmic decongestant,antihistamine, or
             decongestant/antihistamine combinations 3 days; Other anticholinergic agents 3 days;
             Immunotherapy injection 1 day.

          -  Other drugs should only be permitted if they are not expected to interfere with the
             ability of the subject to participate in the study.

          -  Non-steroidal anti-inflammatory agents are not allowed for 2 days prior to each
             treatment visit day through 25 hours post-dose (low-dose cardiac prophylaxis is
             allowed).

          -  Use of any medications or agents that are not specified above that may confound the
             interpretation of the results:

          -  Caffeine within 6 hours prior to each visit (coffee, tea, cola, and sodas, including
             Mountain Dew and Surge)

          -  Decaffeinated coffee, tea and colas within 6 hours of each visit

          -  Alcohol within 24 hours prior to each study visit

          -  Chocolate within 6 hours prior to each visit

          -  Antacids within +/- minus2 hours of investigational product dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phyllis Diener</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Terfenadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

